Sermorelin is the GHRH(1-29) fragment that tells the pituitary to release its own growth hormone.

The short version

Sermorelin is a lab-made copy of the front end of a brain hormone. The brain makes GHRH (its own "release growth hormone" signal); sermorelin is the first 29 building blocks of that signal — the shortest piece that still works fully. Given to the body, it tells the pituitary gland to release the body's own growth hormone in natural bursts, which then raises IGF-1 (a growth signal the liver makes when growth hormone rises). It was once an FDA-approved children's medicine, was pulled from the US market in 2008 for business reasons (not safety), and is now made by compounding pharmacies. This page summarizes what studies have measured; the material described here is research-grade, supplied for laboratory work, and nothing here is dosing advice.

What sermorelin is

Sermorelin (sermorelin acetate, GHRH(1-29)NH2 / GRF(1-29)) is a synthetic 29-amino-acid peptide. It corresponds to the amino-terminal 1-29 fragment of endogenous 44-residue human growth-hormone-releasing hormone (GHRH), and it is the shortest fragment that retains full activity at the GHRH receptor ^[12]. Molecular weight is 3357.9 Da; CAS 86168-78-7.

GHRH is a secretagogue — something that tells a gland to release its hormone. Sermorelin reproduces that signal. Rather than supplying growth hormone (GH) from outside, it acts upstream on the pituitary and prompts the gland to release the GH the body already makes. Because endogenous GHRH-driven GH secretion declines with age, the GH/IGF-1 axis is the recurring subject of the adult research ^[11].

This site reads that record as a board of discrete findings. Each panel below carries one result; each quantitative claim points to a study on the full reference list.

How sermorelin stimulates growth hormone

As the active 1-29 fragment of GHRH, sermorelin binds the GHRH receptor (GHRH-R) — a class B G-protein-coupled receptor — on the pituitary's somatotrophs (the GH-producing cells) ^[11]. Receptor binding activates the Gs / adenylate-cyclase / cAMP / protein kinase A (PKA) pathway: cAMP is the cell's internal "go" messenger, and PKA is the enzyme it switches on. That cascade drives GH gene transcription and pulsatile (released in natural bursts, not a steady drip) GH release, plus a trophic — growth-promoting — effect on the somatotrophs themselves.

Downstream, GH raises hepatic IGF-1. Because sermorelin works through the body's own machinery, the somatostatin and IGF-1 negative-feedback brakes stay intact ^[11]. The result, in principle, is reinforcement of the natural pulsatile GH pattern rather than the flat, feedback-overriding elevation that exogenous GH produces — the distinction an editorial framed as a more physiologic approach to adult GH insufficiency ^[4]. The detailed receptor pathway and the comparison with how sermorelin works against direct GH are covered on the published human research page.

What the research examines

Searches for sermorelin benefits return marketing copy; the literature instead spans several distinct, measured questions on the wider GHRH(1-29) class, each reported rather than asserted.

Pediatric growth. In its one historical FDA-approved setting, once-daily subcutaneous GHRH(1-29) accelerated linear growth in GH-deficient children, with first-year height velocity rising from about 4.1 cm/year to roughly 7-8 cm/year, and without excessive IGF-1 generation ^[1].

The aging GH/IGF-1 axis. In healthy older men (mean 68 years), 0.5 mg and 1 mg subcutaneously twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1; after the high dose, those parameters no longer differed from young men ^[2].

Cognition and neuroendocrine signalling. A randomized controlled trial of a stabilized GHRH analog (tesamorelin) recorded a favorable effect on cognition over 20 weeks ^[6]. This is the site's sermorelin and cognition lens — and its central caveat, that most of the cognition evidence uses related analogs rather than sermorelin itself, is stated plainly there.

These are research findings on the GH/IGF-1 axis. They are not anti-aging claims, and the site does not present sermorelin as a treatment.

Sermorelin as a research peptide

As a sermorelin peptide entry in the research record, sermorelin is studied as the prototypical native GHRH agonist — the molecular reference point against which longer-acting GHRH analogs are designed. Its defining property is brevity: the native peptide clears from plasma in roughly 10-12 minutes, yet a single dose elevates serum GH for about 3 hours ^[3]. That short half-life is precisely why half-life-extension chemistry — D-Ala2 substitution, PEGylation, and the albumin-binding DAC technology — was developed for the next generation of analogs ^[10].

That makes the peptide a useful comparator. The sermorelin vs CJC-1295 page sets the native 1-29 fragment against a long-acting analog built specifically to overcome that clearance. Lyophilized sermorelin acetate is supplied as a powder because aqueous peptide solutions degrade; it is reconstituted before study use.

Regulatory status, stated plainly

Sermorelin's approval history is frequently misstated, so the site states it precisely. Sermorelin was an FDA-approved prescription drug (NDA 020443) for the evaluation and treatment of growth hormone deficiency and short stature in children. It was withdrawn from the US market in 2008 for commercial reasons — not because of any safety or efficacy problem ^[15].

It is therefore neither a currently marketed finished drug nor a "never approved" compound. It is now prepared by compounding pharmacies and is treated as a long-standing Category 1 bulk drug substance under FDA's interim Section 503A framework, with final guidance issued in January 2025 ^[15]. The regulatory status of sermorelin is addressed further in the FAQ. The material discussed on this site is research-grade GHRH(1-29) supplied for laboratory work — not a compounded prescription and not a finished medicine.

Common questions, in brief

Several questions recur often enough to answer on the front board; the full set sits on the reported and theoretical concerns page.